Germline Testing in Prostate Cancer: When and Who to Test.
Oncology (Williston Park)
; 35(10): 645-653, 2021 10 20.
Article
en En
| MEDLINE
| ID: mdl-34669358
ABSTRACT
The results of multiple studies have shown that a substantial proportion of men with advanced prostate cancer carry germline DNA repair mutations. Germline testing in prostate cancer may inform treatment decisions and consideration for clinical trials. There are 2 FDA approved PARP inhibitors (PARPi), olaparib (Lynparza) and rucaparib (Rubraca), for the treatment of advanced prostate cancer with DNA repair deficiency. Increasing demand for germline testing in prostate cancer and a shortage of genetic counselors have created a need for alternative care models and encouraged oncologists to take a more active role in performing germline testing. This article summarizes recommendations for germline testing in prostate cancer and describes care models for providing counseling and testing.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Mutación de Línea Germinal
/
Reparación del ADN
/
Inhibidores de Poli(ADP-Ribosa) Polimerasas
Tipo de estudio:
Guideline
/
Prognostic_studies
Límite:
Humans
/
Male
Idioma:
En
Revista:
Oncology (Williston Park)
Asunto de la revista:
NEOPLASIAS
Año:
2021
Tipo del documento:
Article